Please use this identifier to cite or link to this item:
Title: Targeting the Bromodomain-containing protein 4 in ovarian clear cell carcinoma
Authors: Wong, Erica Shiyi
Keywords: DRNTU::Science
Issue Date: 2017
Abstract: Ovarian clear cell carcinoma (OCCC) is the second most common histopathological subtype of ovarian carcinoma (OC), making up 5-25% of all OC. Current treatment utilizing combination chemotherapy with cisplatin and paclitaxel have low efficacy with a 5-year survival rate of only 12%. Bromodomain-containing protein 4 (BRD4) is known to be upregulated in OCCC and is also involved in many cancer progression pathways, thus making it an important therapeutic target. Additionally, there are reported cases of OCCC gaining resistance to BRD4 inhibitor treatment, which may be due to adaptive kinome reprogramming. Thus, this study aims to elucidate the role of BRD4 in OCCC, as well as identify potential alternative combination therapies involving BRD4 and kinase inhibitors to combat OCCC. ShRNA-mediated BRD4 knockdown (KD) cells were generated and cell proliferation, migration and invasion assays performed. The study found that cell proliferation, migration and invasion capabilities were reduced in BRD4 KD cells, implying that BRD4 plays an important role in tumour growth and metastasis. CRISPR/Cas9 mediated BRD4 knockout (KO) cells are currently being generated for screening of kinase inhibitor libraries. It is hoped that this would lead to identification of potential combination therapies for OCCC.
Rights: Nanyang Technological University
Fulltext Permission: restricted
Fulltext Availability: With Fulltext
Appears in Collections:SBS Student Reports (FYP/IA/PA/PI)

Files in This Item:
File Description SizeFormat 
BRD4 Erica FYP Thesis Final Signed.pdf
  Restricted Access
Main article1.57 MBAdobe PDFView/Open

Page view(s)

Updated on Jun 22, 2021


Updated on Jun 22, 2021

Google ScholarTM


Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.